Uric acid and HMGB1 are involved in the induction of autoantibodies elicited in mice infected with mouse hepatitis virus A59

References

• Coutelier J-P, Coulie PG, Wauters P, Heremans H, Van Der Logt JTM. In vivo polyclonal B-lymphocyte activation elicited by murine viruses. J Virol. 1990; 64:5383–5388.
   PubMed Web of Science ®Google Scholar
• Godfraind C, Coutelier J-P. Morphological analysis of mouse hepatitis virus A59-induced pathology with regard to viral receptor expression. Histol Histopathol. 1998; 13:181–199.
   PubMed Web of Science ®Google Scholar
• Mathieu PA, Gómez KA, Coutelier J-P, Retegui LA. Identification of two liver proteins recognized by autoantibodies elicited in mice infected with mouse hepatitis virus A59. Eur J Immunol. 1996; 31:1447–1455.
   Google Scholar
• Mathieu PA, Gómez KA, Coutelier J-P, Retegui LA. Sequence similarity and structural homologies are involved in the autoimmune response elicited by mouse hepatitis virus A59. J Autoimmun. 2004; 23:117–126.
   PubMed Web of Science ®Google Scholar
• Duhalde-Vega M, Loureiro ME, Mathieu PA, Retegui LA. The peptide specificities of the autoantibodies elicited by mouse hepatitis virus A59. J Autoimmun. 2006; 27:203–209.
   PubMed Web of Science ®Google Scholar
• Duhalde-Vega M, Aparicio JL, Retegui LA. Fine specificity of autoantibodies induced by mouse hepatitis virus A59. Viral Immunol. 2009; 22:287–294.
   PubMed Web of Science ®Google Scholar
• Routsias JG, Tzioufas AG, Moutsopoulos HM. The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clin Chim Acta. 2004; 340:1–25.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: A renewed sense of self. Science. 2002; 296:301–305.
   PubMed Web of Science ®Google Scholar
• Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008; 8:279–289.
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003; 425:516–521.
   PubMed Web of Science ®Google Scholar
• Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med. 2008; 14:476–484.
   PubMed Web of Science ®Google Scholar
• Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008; 10:1–10.
   Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem. 1951; 193:265–275.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–254.
   PubMed Web of Science ®Google Scholar
• Hu DH, Moore AM, Thomsen LL, Brindle MK. Uric acid promotes tumor immune rejection. Cancer Res. 2004; 64:5059–5062.
   PubMed Web of Science ®Google Scholar
• Tasci I, Deveci S, Isik AT, Comert B, Akay C, Mas N, Inal V, Yamanel L, Mas MR. Allopurinol in rat chronic pancreatitis: Effects on pancreatic stellate cell activation. Pancreas. 2007; 35:366–371.
   PubMed Web of Science ®Google Scholar
• Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA. 2002; 99:12351–12356.
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Delude RL, Fink MP. Dose-dependent effect of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med. 2003; 29:2050–2058.
   PubMed Web of Science ®Google Scholar
• Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001; 60:981–983.
   PubMed Web of Science ®Google Scholar
• Kato C, Sato K, Wakabayashi A, Eishi Y. The effects of allopurinol on immune function in normal BALB/c and SCID mice. Int Immunopharmacol. 2000; 7:547–556.
   Google Scholar
• Yang Z-Y, Ling Y, Yin T, Tao J, Xion J-X, Wu H-S, Wang C-Y. Delayed ethyl pyruvate therapy attenuates experimental severe acute pancreatitis via reduced serum high mobility group box 1 in rats. World J Gastroenterol. 2008; 14:4546–4550.
   PubMed Web of Science ®Google Scholar
• Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4:372–377.
   PubMed Web of Science ®Google Scholar
• Fink MP. Ethyl pyruvate: A novel anti-inflammatory agent. J Intern Med. 2007; 261:349–362.
   PubMed Web of Science ®Google Scholar
• Hang Y, Englert JA, Yang R, Delude RL, Fink MP. Ethyl piruvate inhibits nuclear factor-kB-dependent by directly targeted p65. J Pharmacol Exp Ther. 2005; 312:1097–1105.
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009; 9:353–362.
   PubMed Web of Science ®Google Scholar
• Plotz PH. The autoantibody repertoire: Searching for order. Nat Rev Immunol. 2003; 3:73–78.
   PubMed Web of Science ®Google Scholar
• Aparicio JL, Duhalde-Vega M, Loureiro ME, Retegui LA. The autoimmune response induced by mouse hepatitis virus A59 is expanded by a hepatotoxic agent. Int Immunopharmacol. 2009; 9:627–631.
   PubMed Web of Science ®Google Scholar
• Ma X, Jia YT, Qiu DK. Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: Involvement of nuclear factor kappa B. World J Gastroenterol. 2007; 13:4249–4254.
   PubMed Web of Science ®Google Scholar
• Lim SC, Choi JE, Kim CH, Duong HQ, Jeong GA, Kang HS, Han SI. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med. 2007; 20:187–218.
   PubMed Web of Science ®Google Scholar
• Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol. 2008; 2:160–167.
   Google Scholar
• Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008; 11:4026–4030.
   Google Scholar
• Campana L, Bosurgi L, Rovere-Querini P. HMGB1: A two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008; 20:1–6.
   PubMed Web of Science ®Google Scholar
• Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007; 19:615–622.
   PubMed Web of Science ®Google Scholar
• Schroeder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger?. Science. 2010; 327:296–300.
   PubMed Web of Science ®Google Scholar
• Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol. 2008; 180:2531–2537.
   PubMed Web of Science ®Google Scholar
• Grus FH, Augustin AJ, Loeffler K, Lutz J, Pfeiffer N. Immunological effects of allopurinol in the treatment of experimental autoimmune uveitis (EAU) after onset of the disease. Eur J Ophthalmol. 2003; 13:185–191.
   PubMed Web of Science ®Google Scholar
• Namazi MR. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int Immunopharmacol. 2004; 4:349–353.
   PubMed Web of Science ®Google Scholar
• Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008; 324:1–7.
   PubMed Web of Science ®Google Scholar